Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.40
0.0000
Post-market: 70.400.00000.00%19:30 EDT
Volume:615.74K
Turnover:43.32M
Market Cap:3.91B
PE:6.34
High:70.61
Open:70.61
Low:70.09
Close:70.40
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:1.19
T/O Rate:1.11%
Dividend:0.81
Dividend Rate:1.15%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.40
PE(LYR):23.01

Loading ...

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Yesterday

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
Yesterday

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
Yesterday

Abbvie - Approved to Participate in Federal 340B Rebate Model Pilot Program

THOMSON REUTERS
·
Yesterday

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Yesterday

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Yesterday

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Yesterday

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Yesterday

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Yesterday

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live
·
Yesterday

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Yesterday

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
Yesterday

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Jobs Data

MT Newswires Live
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Oct 02

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Oct 02

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Oct 02